Current Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung Cancer

The treatment paradigm for metastatic non-small cell, non-squamous lung cancer is continuously evolving due to new treatment options and our increasing knowledge of molecular signal pathways. As a result of treatments becoming more efficacious and more personalized, survival for selected groups of n...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 7; p. 38
Main Author Melosky, Barbara
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 20.03.2017
Subjects
Oncology
metastatic non-squamous non-small cell lung cancer
targeted therapy
epidermal growth factor receptor
anaplastic lymphoma kinase
systemic therapy
chemotherapy
algorithm
Online AccessGet full text
ISSN2234-943X
2234-943X
DOI10.3389/fonc.2017.00038

Cover

More Information
Summary:The treatment paradigm for metastatic non-small cell, non-squamous lung cancer is continuously evolving due to new treatment options and our increasing knowledge of molecular signal pathways. As a result of treatments becoming more efficacious and more personalized, survival for selected groups of non-small cell lung cancer (NSCLC) patients is increasing. In this paper, three algorithms will be presented for treating patients with metastatic non-squamous, NSCLC. These include treatment algorithms for NSCLC patients whose tumors have mutations, rearrangements, or wild-type/wild-type tumors. As the world of immunotherapy continues to evolve quickly, a future algorithm will also be presented.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Specialty section: This article was submitted to Thoracic Oncology, a section of the journal Frontiers in Oncology
Reviewed by: Shirish M. Gadgeel, Wayne State University, USA; Weiqiang Zhao, The Ohio State University Wexner Medical Center, USA; Gregory Alan Otterson, Ohio State University at Columbus, USA
Edited by: Miguel Angel Villalona, Baptist Health South Florida, USA
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2017.00038